ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
A multidimensional pan-cancer analysis of CD47 and its role in promoting malignant phenotype in pancreatic adenocarcinoma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCD47 is a widely expressed member of the immunoglobulin superfamily and plays important roles in cell proliferation, adhesion, and immune evasion. Previous studies have shown that CD47 contributes to tumor development by inhibiting immune-mediated clearance in multiple cancer types. However, the expression patterns of CD47 across different malignancies, its prognostic relevance, and its associations with the tumor immune microenvironment remain incompletely elucidated in a pan-cancer context.
methodsIn this study, we performed a comprehensive pan-cancer analysis using publicly available multi-omics datasets to examine CD47 expression patterns, clinical relevance, and immune features across 34 tumor types, together with their associations with patient prognosis, genomic instability indicators, tumor microenvironment composition, and biomarkers relevant to immunotherapy.
resultsThe results showed that high CD47 expression was associated with unfavorable survival outcomes in multiple cancers and was significantly correlated with immune microenvironment characteristics and several immunotherapy-related biomarkers, although notable heterogeneity was observed among different tumor types. Based on the pan-cancer screening results, pancreatic adenocarcinoma was selected for further investigation. In pancreatic adenocarcinoma, CD47 was significantly upregulated and associated with higher histological grade and increased macrophage infiltration. In vitro experiments confirmed that CD47 knockdown reduces pancreatic cancer cell proliferation, migration, and invasion. In addition, in co-culture systems, treatment with RRx-001 was associated with enhanced macrophage phagocytic activity and altered expression of macrophage-related markers.
conclusionsIn conclusion, this study systematically characterizes the clinical and immunological associations of CD47 across multiple cancers and highlights its potential role in pancreatic adenocarcinoma, supporting the further investigation of CD47 as a therapeutic target.
Indexed as
Identifiers
41697531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.